Skip to main content
. 2020 Oct 28;10:18489. doi: 10.1038/s41598-020-75578-5

Figure 1.

Figure 1

Dinaciclib treatment and expression of CDK2/5/9 in CCA. (A) CHNG6, patient derived xenograft cells (PDXC) were subjected to a high throughput-drug screening and is significantly sensitive to dinaciclib at low nanomolar concentrations. (B) Relative mRNA expression of CDK2/5/9 are overexpressed in cholangiocarcinoma samples relative to normal samples from cBioportal database. mRNA expression was available for thirty-five tumor and ten normal samples. Expression of CDK’s was normalized with normal samples and the data presented as box plots. (C) Copy number analysis of thirty-five tumor samples from the cBioportal database indicates subsets of CCA samples with copy number gain in CDK2, CDK5 and CDK9. Copy number gain is presented in percentages.